Phenotypes associated with this allele
neoplasm
|
|
• compared with Tg(IghMyc)22Bri mice
|
immune system
|
|
• 7.5-fold compared with Tg(IghMyc)22Bri mice
|
|
|
• 60-fold compared with Cd79atm1(Cre)Reth/Cd79a+ or Tg(IghMyc)22Bri mice
|
neoplasm
|
|
• compared with Tg(IghMyc)22Bri mice
|
|
|
• compared with Tg(IghMyc)22Bri mice
• however, the range to tumor types is the same
|
cellular
hematopoietic system
|
|
• 7.5-fold compared with Tg(IghMyc)22Bri mice
|
|
|
• 60-fold compared with Cd79atm1(Cre)Reth/Cd79a+ or Tg(IghMyc)22Bri mice
|
immune system
neoplasm
|
|
• compared with Tg(IghMyc)22Bri mice
|
hematopoietic system
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(IghMyc)22Bri mutation
(1 available)
Xiaptm1Hs mutation
(1 available);
any
Xiap mutation
(37 available)
|
|
|
mortality/aging
 N |
• mice exhibit increased survival compared to Tg(IghMyc)22Bri mice
|
immune system
|
|
• compared to in Tg(IghMyc)22Bri mice
|
|
|
• compared to in Tg(IghMyc)22Bri mice
|
|
|
• peripheral white blood counts are lower than in Tg(IghMyc)22Bri mice that develop leukemia
|
hematopoietic system
|
|
• compared to in Tg(IghMyc)22Bri mice
|
|
|
• compared to in Tg(IghMyc)22Bri mice
|
|
|
• peripheral white blood counts are lower than in Tg(IghMyc)22Bri mice that develop leukemia
|
cellular
|
|
• compared to in Tg(IghMyc)22Bri mice
|
|
|
• compared to in Tg(IghMyc)22Bri mice
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Mdm2tm1.1Ypz mutation
(3 available);
any
Mdm2 mutation
(54 available)
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
mortality/aging
|
|
• median survival is 15 weeks
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Mdm2tm1.1Ypz mutation
(3 available);
any
Mdm2 mutation
(54 available)
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
mortality/aging
|
|
• median survival is 9 weeks
|
immune system
neoplasm
|
|
• lymphomagenesis is accelerated compared to in Tg(IghMyc)22Bri mice
|
liver/biliary system
hematopoietic system
endocrine/exocrine glands
growth/size/body
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Prdm11tm1.1Ahl mutation
(0 available);
any
Prdm11 mutation
(22 available)
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
neoplasm
|
|
• mice show accelerated development of B-cell lymphomas, with a median survival of 94 days versus 113 days in single Tg(IghMyc)22Bri mice
• however, no difference in tumor load or in proliferation are seen and no differences in cell cycle profiles or apoptotic index are seen
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Kat5tm1Jwl mutation
(0 available);
any
Kat5 mutation
(25 available)
Tg(IghMyc)22Bri mutation
(1 available)
Trp53tm1Tyj mutation
(12 available);
any
Trp53 mutation
(232 available)
|
|
|
mortality/aging
|
|
• mice die prior to 20 weeks of age
|
neoplasm
|
|
• mice exhibit an earlier age of onset and enhanced penetrance of B cell lymphomas compared to in Tg(IghMyc)22Bri mice
|
mortality/aging
|
|
• the median lifespan of 31 days
|
neoplasm
|
|
• based on median survival time, mice carrying single Trp53tm1Brd allele were no more resistant to tumor formation induced by myc than mice with homozygous wild-type Ppm1d+ allele
|
mortality/aging
|
|
• the median lifespan of >130 days
|
neoplasm
|
|
• similar to mice carrying double Ppm1dtm1Lad allele without Cdkn2atm1Cjs allele, based on increased median survival time, mice carrying single Cdkn2atm1Cjs allele were considerably more resistant to tumor formation induced by myc than mice with homozygous wild-type Ppm1d+ allele
|
mortality/aging
|
|
• the median lifespan of 69 days
|
neoplasm
|
|
• based on median survival time, mice carrying double Atmtm1Awb allele were no more resistant to tumor formation induced by myc than mice with homozygous wild-type Ppm1d+ allele
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(IghMyc)22Bri mutation
(1 available)
Trp53tm2.1Thst mutation
(1 available);
any
Trp53 mutation
(232 available)
|
|
|
mortality/aging
|
|
• similar to mice with a null Trp53 allele, mice exhibit shorter survival than those with wild-type Trp53
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Crebbptm2Pkb mutation
(2 available);
any
Crebbp mutation
(99 available)
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
neoplasm
|
|
• on a hybrid background presence of a single Crebbtm2Pkb allele decreased the median survival time by about 8-10 weeks compared to wild-type transgenic littermates
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cul9tm1.2Yxi mutation
(0 available);
any
Cul9 mutation
(108 available)
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
mortality/aging
|
|
• lymphoma-free survival is 85.1 months compared with 126.4 months for Tg(IghMyc)22Bri mice
|
neoplasm
|
|
• lymphoma cell clusters spread throughout the liver parenchyma and exhibit various degrees of lung and pancreas infiltration unlike in Tg(IghMyc)22Bri mice
|
|
|
• mice develop lymphomas by 25 days of age
• 3 of 5 mice younger than 2 months of age develop lymphomas unlike Tg(IghMyc)22Bri mice
• by 5 months, 10 of 10 of mice develop lymphomas compared with 6 of 9 Tg(IghMyc)22Bri mice
|
|
|
• all lymphomas are B cell or pre-B cell lymphomas
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cul9tm1.2Yxi mutation
(0 available);
any
Cul9 mutation
(108 available)
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
mortality/aging
|
|
• lymphoma-free survival is 108.9 months compared with 126.4 months for Tg(IghMyc)22Bri mice
|
neoplasm
|
|
• lymphoma cell clusters spread throughout the liver parenchyma and exhibit various degrees of lung and pancreas infiltration unlike in Tg(IghMyc)22Bri mice
|
|
|
• 3 of 5 mice younger than 2 months of age develop lymphomas unlike Tg(IghMyc)22Bri mice
• by 5 months, 16 of 20 of mice develop lymphomas compared with 6 of 9 Tg(IghMyc)22Bri mice
|
|
|
• all lymphomas are B cell or pre-B cell lymphomas
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Plcg2tm1Jni mutation
(2 available);
any
Plcg2 mutation
(74 available)
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
mortality/aging
|
|
• mean mortality is 10 weeks
|
immune system
neoplasm
|
|
• development of lymphoma is accelerated compared to in Tg(IghMyc)22Bri mice
|
|
|
• lymphomas are composed of large pre-B cells unlike in Tg(IghMyc)22Bri mice
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(IghMyc)22Bri mutation
(1 available)
Trp53tm1.1Thst mutation
(1 available);
any
Trp53 mutation
(232 available)
|
|
|
mortality/aging
|
|
• compared with Tg(IghMyc)22Bri mice
• median survival is 10 days longer than in Trp53tm1Thst/Trp53+ Tg(IghMyc)22Bri mice
|
neoplasm
|
|
• with increased apoptosis and senescence staining in tumors from Tg(IghMyc)22Bri mice
|
Allelic
Composition |
Kat5tm1Jwl/Kat5+
Tg(IghMyc)22Bri/0
|
|
Genetic
Background |
involves: 129S1/Sv * 129X1/SvJ * C57BL * C57BL/6 * SJL |
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Kat5tm1Jwl mutation
(0 available);
any
Kat5 mutation
(25 available)
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
mortality/aging
|
|
• mice die prior to 30 weeks of age
|
neoplasm
|
|
• mice exhibit an earlier age of onset and enhanced penetrance of B cell lymphomas compared to in Tg(IghMyc)22Bri mice
• tumor cells exhibit replacement of the knock-out allele with a wild-type allele
|
immune system
|
|
• B cells exhibit severely impaired Myc-induced DNA damage repair
|
homeostasis/metabolism
cellular
|
|
• B cells exhibit severely impaired Myc-induced DNA damage repair
• however, DNA damage repair following ionizing radiation exposure is normal
|
hematopoietic system
|
|
• B cells exhibit severely impaired Myc-induced DNA damage repair
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(IghMyc)22Bri mutation
(1 available)
Trp53tm1Thst mutation
(2 available);
any
Trp53 mutation
(232 available)
|
|
|
mortality/aging
|
|
• compared with Tg(IghMyc)22Bri mice
|
neoplasm
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Npm1tm1Ppp mutation
(1 available);
any
Npm1 mutation
(33 available)
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
neoplasm
|
|
• all lymphomas have numerical chromosomal abnormalities unlike in Tg(IghMyc)22Bri animals, however only 1 of 4 tumors show structural abnormalities that are seen in the transgenic mice alone
|
|
|
• B cell lymphoma onset is significantly accelerated compared to Tg(IghMyc)22Bri mice
• all lymphomas have numerical chromosomal abnormalities unlike Tg(IghMyc)22Bri animals, however only 1 of 4 tumors show structural abnormalities that are seen in the transgenic mice alone
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Dnmt1tm1(tetO-BCL2)Sjk mutation
(0 available);
any
Dnmt1 mutation
(108 available)
Tg(IghMyc)22Bri mutation
(1 available)
Tg(MMTVtTA)1Mam mutation
(3 available)
|
|
|
mortality/aging
|
|
• without doxycycline treatment median survival is 82 days, with doxycycline treatment the improves to 145 days
|
neoplasm
|
|
• in the absence of doxycycline, lymphoblastic leukemia is seen by 2 weeks of age
• in 5 - 7 week old triple transgenics with lymphoblastic leukemia doxycycline treatment resulted in normalization of the WBC count and restoration of normal hematopoiesis
|
|
|
• bulky B cell derived lymphomas, similar to those in Tg(IghMyc)22Bri single transgenics, are seen in older triple transgenics after treatment with doxycycline
|
behavior/neurological
|
|
• transgenics with leukemia are lethargic, doxycycline treatment returns activity levels to normal
|
hematopoietic system
|
|
• in the absence of doxycycline, mutants develop an enlarged spleen with doxycycline treatment the spleen returns to its normal size
|
immune system
|
|
• in the absence of doxycycline, mutants develop an enlarged spleen with doxycycline treatment the spleen returns to its normal size
|
growth/size/body
|
|
• in the absence of doxycycline, mutants develop an enlarged spleen with doxycycline treatment the spleen returns to its normal size
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Mirc1tm2.1Aven mutation
(1 available);
any
Mirc1 mutation
(6 available)
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
cellular
|
|
• increase in pre-B cell apoptosis as compared to mice carrying Tg(IghMyc)22Bri alone
|
mortality/aging
|
|
• increase in survival as compared to mice carrying Tg(IghMyc)22Bri alone and mice carrying Tg(IghMyc)22Bri and heterozygous for Mirc1 tm2.1Aven
|
hematopoietic system
|
|
• increase in pre-B cell apoptosis as compared to mice carrying Tg(IghMyc)22Bri alone
|
|
|
• bone marrow of 5 week old mice is not characterized by an accumulation of pre-B cells as compared to Tg(IghMyc)22Bri
|
immune system
|
|
• increase in pre-B cell apoptosis as compared to mice carrying Tg(IghMyc)22Bri alone
|
|
|
• bone marrow of 5 week old mice is not characterized by an accumulation of pre-B cells as compared to Tg(IghMyc)22Bri
|
neoplasm
|
|
• immunophenotype of B cell lymphomas is altered (increase in in IgM+ tumors) as compared to Tg(IghMyc)22Bri alone
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Mirc1tm2.1Aven mutation
(1 available);
any
Mirc1 mutation
(6 available)
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ep300tm3Pkb mutation
(2 available);
any
Ep300 mutation
(97 available)
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
neoplasm
|
|
• on a C57BL/6 background, surivival of transgenic mutants carrying the mutant Ep300 allele were identical to that of Ep300-sufficient transgenic mice
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Mdm4tm1Glo mutation
(0 available);
any
Mdm4 mutation
(191 available)
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
neoplasm
|
|
• mice develop B cell lymphomas
• however, lymphomagenesis is delayed compared to in Tg(IghMyc)22Bri mice
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ep300tm3Pkb mutation
(2 available);
any
Ep300 mutation
(97 available)
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
neoplasm
|
|
• on a hybrid background presence of a single Ep300tm3Pkb allele decreased the median survival time by about 8-10 weeks compared to wild-type transgenic littermates
|
mortality/aging
|
|
• the median lifespan of 130 days
|
neoplasm
|
|
• similar to mice carrying double Ppm1dtm1Lad allele without Mapk14tm1Dvb allele, based on increased median survival time, mice carrying single Mapk14tm1Dvb allele were considerably more resistant to tumor formation induced by myc than mice with homozygous wild-type Ppm1d+ allele
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ppm1dtm1Lad mutation
(1 available);
any
Ppm1d mutation
(28 available)
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
mortality/aging
|
|
• the median lifespan of 107 days
|
neoplasm
|
|
• mice carrying a single Ppm1dtm1Lad allele were considerably more resistant to tumor formation induced by myc than wild-type transgenic litter mates based on increased median survival time by about 30 days
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ppm1dtm1Lad mutation
(1 available);
any
Ppm1d mutation
(28 available)
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
mortality/aging
|
|
• the median lifespan of 138 days
|
neoplasm
|
|
• mice carrying double Ppm1dtm1Lad allele were considerably more resistant to tumor formation induced by myc than wild-type transgenic litter mates based on increased median survival time by about 60 days
|
mortality/aging
|
|
• mice die prior to 20 weeks of age
|
neoplasm
|
|
• mice exhibit an earlier age of onset and enhanced penetrance of B cell lymphomas compared to in Tg(IghMyc)22Bri mice
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Dmtf1tm1Cjs mutation
(3 available);
any
Dmtf1 mutation
(83 available)
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
neoplasm
|
|
• accelerated tumor formation as compared to mice carrying only Tg(IghMyc)22Bri
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Klrb1btm1.1Apma mutation
(0 available);
any
Klrb1b mutation
(11 available)
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
neoplasm
|
|
• delayed onset of B cell lymphoma compared with Tg(IghMyc)22Bri mice
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Boktm1.1Ast mutation
(0 available);
any
Bok mutation
(21 available)
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
neoplasm
|
|
• as in Tg(IghMyc)22Bri mice
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Igh-Abl1)40Sco mutation
(0 available)
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
neoplasm
|
|
• accelerated development of plasmacytomas compared to single Tg(Igh-Abl1)40Sco transgenic mice, with mice becoming ill between 5 and 8 weeks of age; especially prominent in the intestine
• tumors are oligoclonal and often secrete IgM
• however, double transgenics do not develop pre-B or B lymphomas, as observed in single Tg(IghMyc)22Bri mice
|
immune system
|
|
• 64% of transgenics exhibit enlarged mesenteric lymph nodes due to engorgement with plasmacytoma cells
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(BCL2)22Wehi mutation
(2 available)
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
mortality/aging
|
|
• animals become terminally ill at 5-6 weeks of age
|
neoplasm
|
|
• masses of lymphoblasts occupy the spleen, lymph nodes and thymus and extensively invade the bone marrow, liver, lungs, and kidneys, an indication of malignant lymphoma
• tumors derive from a cell with the hallmarks of a primitive hematopoietic cell
|
hematopoietic system
|
|
• 50- to 100-fold higher levels of white blood cells compared to controls
|
|
|
• 70% increase in numbers of B cells in bone marrow and spleen
|
|
|
• 30% increase in numbers of pre-B cells in bone marrow and spleen
|
immune system
|
|
• 50- to 100-fold higher levels of white blood cells compared to controls
|
|
|
• 70% increase in numbers of B cells in bone marrow and spleen
|
|
|
• 30% increase in numbers of pre-B cells in bone marrow and spleen
|
endocrine/exocrine glands
growth/size/body
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Klrk1tm1Dhr mutation
(3 available);
any
Klrk1 mutation
(24 available)
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
neoplasm
|
|
• lymphomas develop significantly earlier in these mice than in mice carrying the transgene on a wild-type background
• the mean time of onset is 7 weeks earlier than in the control group with all mice have detectable tumors by 30 weeks of age
• the tumors consist of a mix pre-B and B cells lymphomas
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(IghMyc)22Bri mutation
(1 available)
Tg(Igk-V21-Bax)1967Bvn mutation
(0 available)
|
|
|
mortality/aging
|
|
• 50% of double transgenics die of a lymphoproliferative disorder by 5.5 weeks
|
neoplasm
|
|
• multifocal to coalescent infiltrations of mononuclear cells with large round to polygonal hypochromatic nuclei are seen in the kidneys, spleen, lymph node, liver, ung, heart, thymus, pancreas, and sternal bone marrow
|
|
|
• osteolytic lesions with cheets of pleomorphic plasmacytic cells adjacent to lysed osseous trabeculae are seen
|
hematopoietic system
|
|
• 4 - 6 week old double transgenic exhibit severe splenomegaly
|
|
|
• the number of immature/transitional B cells is increased
|
immune system
|
|
• 4 - 6 week old double transgenic exhibit severe splenomegaly
|
|
|
• the number of immature/transitional B cells is increased
|
liver/biliary system
|
|
• multiple beige nodules up to 2 mm in diameter are seen
|
growth/size/body
|
|
• 4 - 6 week old double transgenic exhibit severe splenomegaly
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Prps2tm1a(KOMP)Wtsi mutation
(0 available);
any
Prps2 mutation
(13 available)
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
mortality/aging
 |
• about 60% of mice live beyond 200 days at which point most mice carrying the transgene alone have died
|
neoplasm
|
|
• dramatic delay in tumor initiation compared to mice carrying the transgene alone
|
hematopoietic system
|
N |
• overall rate of protein synthesis in B lymphocytes is reduced towards normal levels unlik in mice carrying Tg(IghMyc)22Bri alone
|
|
|
• B lymphocytes show increased glucose uptake and increased rate of glucose oxidation compared to mice carrying the transgene alone
• no alterations in mitochondrial mass or mitochondrial membrane potential are detected
|
|
|
• dramatic increase in B lymphocytes compared to mice carrying the transgene alone
|
immune system
|
|
• B lymphocytes show increased glucose uptake and increased rate of glucose oxidation compared to mice carrying the transgene alone
• no alterations in mitochondrial mass or mitochondrial membrane potential are detected
|
|
|
• dramatic increase in B lymphocytes compared to mice carrying the transgene alone
|
cellular
|
|
• dramatic increase in B lymphocytes compared to mice carrying the transgene alone
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Bcl2l11tm3.1Boui mutation
(0 available);
any
Bcl2l11 mutation
(32 available)
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
mortality/aging
|
|
• median lifespan is 110 days, which is similar to single Tg(IghMyc)22Bri hemizygotes
|
neoplasm
|
|
• mutants exhibit a mixture of sIg- pre-B lymphoma (~55%) and sIg+ B lymphoma (~45%)
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Bcl2l11tm1.1Boui mutation
(0 available);
any
Bcl2l11 mutation
(32 available)
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
mortality/aging
|
|
• median survival of 50 days
|
neoplasm
|
|
• mutants exhibit a mixture of sIg- pre-B lymphoma (~55%) and sIg+ B lymphoma (~45%)
|
hematopoietic system
|
|
• increase in white blood cell count is higher than in single Tg(IghMyc)22Bri hemizygotes
|
immune system
|
|
• increase in white blood cell count is higher than in single Tg(IghMyc)22Bri hemizygotes
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Bcl2l11tm2.1Boui mutation
(0 available);
any
Bcl2l11 mutation
(32 available)
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
mortality/aging
|
|
• average survival is 70 days; survival is decreased compared to single Tg(IghMyc)22Bri hemizygotes which live to about 100 days
|
neoplasm
|
|
• mutants exhibit a mixture of sIg- pre-B lymphoma (~55%) and sIg+ B lymphoma (~45%)
|
hematopoietic system
|
|
• white blood cell counts are increased to a similar extent as in single Tg(IghMyc)22Bri hemizygotes
|
immune system
|
|
• white blood cell counts are increased to a similar extent as in single Tg(IghMyc)22Bri hemizygotes
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Bcl2l11tm2.1Boui mutation
(0 available);
any
Bcl2l11 mutation
(32 available)
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
mortality/aging
|
|
• median survival of 58 days
|
neoplasm
|
|
• mutants exhibit a mixture of sIg- pre-B lymphoma (~60%) and sIg+ B lymphoma (~40%)
|
hematopoietic system
|
|
• increase in white blood cell count is higher than in single Tg(IghMyc)22Bri hemizygotes
|
immune system
|
|
• increase in white blood cell count is higher than in single Tg(IghMyc)22Bri hemizygotes
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Bcl2l11tm1.1Boui mutation
(0 available);
any
Bcl2l11 mutation
(32 available)
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
mortality/aging
|
|
• median survival is 64 days; survival is decreased compared to single Tg(IghMyc)22Bri hemizygotes which live to about 100 days
|
neoplasm
|
|
• mutants exhibit a rare incidence of Thy1+ T lymphoma
|
|
|
• mutants exhibit a mixture of sIg- pre-B lymphoma (~65%) and sIg+ B lymphoma (~35%)
|
hematopoietic system
|
|
• white blood cell counts are increased to a similar extent as in single Tg(IghMyc)22Bri hemizygotes
|
immune system
|
|
• white blood cell counts are increased to a similar extent as in single Tg(IghMyc)22Bri hemizygotes
|
endocrine/exocrine glands
|
|
• mutants exhibit a rare incidence of Thy1+ T lymphoma
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Bcl2l11tm3.1Boui mutation
(0 available);
any
Bcl2l11 mutation
(32 available)
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
mortality/aging
|
|
• median lifespan is 84 days, which is not statistically different from single Tg(IghMyc)22Bri hemizygotes
|
neoplasm
|
|
• mutants exhibit a mix of sIg- pre-B lymphoma (~50%) and sIg+ B lymphoma (~50%)
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(EmuSR-tTa)83Bop mutation
(1 available)
Tg(IghMyc)22Bri mutation
(1 available)
Tg(tetO-RNAi:Trp53)ASlowe mutation
(0 available)
|
|
|
mortality/aging
|
|
• mutants become moribund without a large peripheral tumor burden, with a median survival of 82 days
|
neoplasm
|
|
• mutants develop lymphoma, with latency of tumorigenesis reduced compared to single Tg(IghMyc)22Bri/0 mice
• lymphoma-bearing mice treated with doxycycline at the onset of paralysis regain full movement within 2 days of doxycycline treatment, show tumor involution, and live for a further 24-64 days before tumors relapse
|
growth/size/body
|
|
• spleen is enlarged and taken over by B220+ IgM- (pre-B) tumor cells, with lymphoma dissemination into the lymph nodes and liver
|
hematopoietic system
|
|
• spleen is enlarged and taken over by B220+ IgM- (pre-B) tumor cells, with lymphoma dissemination into the lymph nodes and liver
|
immune system
|
|
• spleen is enlarged and taken over by B220+ IgM- (pre-B) tumor cells, with lymphoma dissemination into the lymph nodes and liver
|
behavior/neurological
|
|
• partial hind leg paralysis is seen in some mutants, most likely attributed to lymphoma
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Fnip1LPAB.1 mutation
(0 available);
any
Fnip1 mutation
(59 available)
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
neoplasm
|
N |
• pre-B cell lymphomagenesis induced by c-Myc expression is inhibited
|
immune system
|
|
• of B220+CD43+ Emu-Myc pre-B cells
|
cellular
|
|
• of B220+CD43+ Emu-Myc pre-B cells
|
hematopoietic system
|
|
• of B220+CD43+ Emu-Myc pre-B cells
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(IghMyc)22Bri mutation
(1 available)
Ube2otm1.1(KOMP)Mbp mutation
(1 available);
any
Ube2o mutation
(57 available)
|
|
|
mortality/aging
|
|
• as in Tg(IghMyc)22Bri mice
|
neoplasm
|
|
• as in Tg(IghMyc)22Bri mice
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cks1btm1Sir mutation
(0 available);
any
Cks1b mutation
(11 available)
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
mortality/aging
|
|
• mean survival after lymphomas develop is 268 days compared to 91 days in Tg(IghMyc)22Bri mice and 101 days in Tg(IghMyc)22Bri Cks1btm1Sir heterozygotes
|
neoplasm
|
|
• only 1 of 9 diseased mice show moderate bone marrow infiltration and none presented with liver or meningeal infiltrates present in Tg(IghMyc)22Bri mice
|
|
|
• delayed development of lymphomas compared to Tg(IghMyc)22Bri mice
|
immune system
|
|
• severely impaired proliferative response compared to Tg(IghMyc)22Bri mice
|
|
|
• 5.4+/-0.4x106ul compared to 6.9+/-0.4x106ul in Tg(IghMyc)22Bri mice
|
|
|
• at 4 weeks, mice have significantly smaller spleens than Tg(IghMyc)22Bri counter parts (83+/-11mg compared to 157+/-7mg)
|
hematopoietic system
|
|
• severely impaired proliferative response compared to Tg(IghMyc)22Bri mice
|
|
|
• 5.4+/-0.4x106ul compared to 6.9+/-0.4x106ul in Tg(IghMyc)22Bri mice
|
|
|
• at 4 weeks, mice have significantly smaller spleens than Tg(IghMyc)22Bri counter parts (83+/-11mg compared to 157+/-7mg)
|
cellular
|
|
• severely impaired proliferative response compared to Tg(IghMyc)22Bri mice
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cks1btm1Sir mutation
(0 available);
any
Cks1b mutation
(11 available)
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
mortality/aging
|
|
• mean survival after lymphomas development is 101 days
|
neoplasm
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Pknox1tm1Ngc mutation
(0 available);
any
Pknox1 mutation
(90 available)
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
Pro-B tumor in Pknox1tm1Ngc/Pknox1+ Tg(IghMyc)22Bri/0 mice
mortality/aging
|
|
• median survival time is 23 weeks compared with 58 weeks for Tg(IghMyc)22Bri mice
|
immune system
neoplasm
|
|
• accelerated and enhanced immature B cell lymphomas compared with Tg(IghMyc)22Bri mice
|
cellular
hematopoietic system
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(IghMyc)22Bri mutation
(1 available)
Tg(Lck/Emu-Eif4e)#Ppp mutation
(0 available)
|
|
|
neoplasm
|
|
• onset of lymphoma is accelerated compared to single Tg(IghMyc)22Bri transgenic mice
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(ACTB-Eif4e)#Ppp mutation
(0 available)
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
neoplasm
|
|
• onset of lymphoma is accelerated compared to single Tg(IghMyc)22Bri transgenic mice and is evident at less than 1 month of age
|
cellular
|
|
• reduction in apoptosis of splenic B cells at 3 weeks of age, before lymphoma occurrence, compared to single Tg(IghMyc)22Bri transgenic mice
|
immune system
|
|
• reduction in apoptosis of splenic B cells at 3 weeks of age, before lymphoma occurrence, compared to single Tg(IghMyc)22Bri transgenic mice
|
hematopoietic system
|
|
• reduction in apoptosis of splenic B cells at 3 weeks of age, before lymphoma occurrence, compared to single Tg(IghMyc)22Bri transgenic mice
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
mortality/aging
|
|
• median survival is 20 weeks
|
immune system
|
|
• moderately at 4 weeks of age
|
neoplasm
hematopoietic system
|
|
• moderately at 4 weeks of age
|
growth/size/body
|
|
• moderately at 4 weeks of age
|
Allelic
Composition |
Tg(IghMyc)22Bri/0
|
|
Genetic
Background |
involves: C57BL/6N * SJL |
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
mortality/aging
|
|
• almost all mice die by 200 days of age
|
neoplasm
hematopoietic system
|
|
• in B lymphocytes compared to wild-type controls but reduced compared to mice carrying the transgene and homozygous for Prps2tm1a(KOMP)Wtsi
|
immune system
|
|
• in B lymphocytes compared to wild-type controls but reduced compared to mice carrying the transgene and homozygous for Prps2tm1a(KOMP)Wtsi
|
cellular
|
|
• in B lymphocytes compared to wild-type controls but reduced compared to mice carrying the transgene and homozygous for Prps2tm1a(KOMP)Wtsi
|
Allelic
Composition |
Tg(IghMyc)22Bri/0
|
|
Genetic
Background |
involves: C57BL/6 * SJL |
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
mortality/aging
|
|
• mice die at 6 to 15 weeks of age with 94% of mice dying by 4 months of age
(J:78177)
• median survival is 100 days
(J:186117)
|
neoplasm
|
|
• mice occasionally develop thyoma without involvement of peripheral lymphoid organs
|
|
|
• mice develop multicentric lymphosarcoma associated with leukemia
|
|
|
• 13 of 15 mice develop lymphomas
(J:78177)
• mice develop multicentric lymphosarcoma associated with leukemia
(J:78177)
|
|
|
• lymphomas develop from single B-lymphoid clones at different stages of differentiation
(J:78177)
• mutants exhibit a mixture of sIg- pre-B lymphoma (~40%) and sIg+ B lymphoma (~60%)
(J:186117)
|
|
|
• mice develop multicentric lymphosarcoma associated with leukemia
|
immune system
|
|
• mice exhibit an increased in the number of lymphoblasts in lymph tissues and the blood compared to wild-type mice
|
|
|
• white blood cell counts are increased
|
|
|
• bone marrow from 5 week old mice contains an accumulation of pre-B cells
|
hematopoietic system
|
|
• mice exhibit an increased in the number of lymphoblasts in lymph tissues and the blood compared to wild-type mice
|
|
|
• white blood cell counts are increased
|
|
|
• bone marrow from 5 week old mice contains an accumulation of pre-B cells
|
endocrine/exocrine glands
growth/size/body
Allelic
Composition |
Tg(IghMyc)22Bri/0
|
|
Genetic
Background |
involves: C57BL * C57BL/6 * SJL |
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
mortality/aging
|
|
• mean mortality is 19 weeks
|
neoplasm
Allelic
Composition |
Tg(IghMyc)22Bri/?
|
|
Genetic
Background |
involves: C57BL * C57BL/6 * SJL |
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(IghMyc)22Bri mutation
(1 available)
|
|
|
mortality/aging
|
|
• mean survival after lymphomas develop 91 days
|
neoplasm
|
|
• 6 of 6 mice suffer from dissemination disease with diffuse bone marrow infiltration of B220+ lymphocytes and infiltration of the spleen, liver and meninges
|
immune system
hematopoietic system
growth/size/body
Analysis Tools